The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks LL,
Had not seen that link and see it is about working against 50% of population vs a placebo.
Was just trying to clarify which efficacy end points they were measuring as 50% seems very low and of course would like to see more about what constitutes works so immune response and length of protection.population sub sets etc.
There was a lot of talk over w/ end about anticipated Vax uptake and effect on herd immunity do wonders if the 50% referred to that.
ATB
Ivy, I was referring to this article - the FDA setting the bar for effectiveness at 50%.
https://www.raps.org/news-and-articles/news-articles/2020/6/fda-issues-covid-19-vaccine-guidance-setting-50-ef
"For a vaccine that would be widely deployed against COVID-19, FDA says it expects sponsors to demonstrate that the vaccine is at least 50% effective in a placebo-controlled trial."
Morning LL.
Are you talking about levels of “ herd immunity” as can’t see a 50% effective Vax being Approved.
ATB
WHO have indicated that they want to see very high efficacy rates - I seem to recall it is 90% or higher. However the FDA has set the bar at 50% - so I can understand the reluctance.
Meanwhile the Moderna antibody vaccines trial seem to indicate that a two shot vaccine only lasted 13 weeks in rats.
In at least one country, I read the healthcare and elderly would be vaccinated first (not the UK).
Interesting BBC news right now noting that young people are much more reluctant to take a vaccine, one reason being the belief that they are less vulnerable to getting covid or doing so with serious impacts.. I think this plays further to the need to have a vaccine that is very effective in the most vulnerable groups, including elderly. They cant rely on the less vulnerable/younger taking it in the kinds of percentages that would work as an effective firebreak. I am an expert in med ethics and i would say vaccine effectiveness is really important from the ethics standpoint given the need to weigh benefits of taking against both the known and potential as yet not known detrimental impacts and risks.l of taking vaccines. I am not a clinician but superficially at least it looks like scancell have a point of difference that could make for a very effective vaccine
Ruck,
What happens when the power of publicity increases the radars field of view?
More targets are found but each appears smaller if the display remains the same size; even if the size of the display is increased it adds complexity as there are more targets to analyse and some newly identifies targets may have less well known characteristics.
What we do know
Covidity
"The Company is actively seeking development partners and additional funding (including non-dilutive funding from governments and global institutions) to support the rapid development of this vaccine."
Immunobody
IMO, the interest of big pharma will increase with positive data.
Moditope
We know there has always been interest and this may increase as the modi1 trial gets nearer.
Then we also know that we have a TCR collaboration with Biontech and we don't quite know at what stage this is at.
Avidity/TaGs
We are told
"Advanced commercial discussions are currently underway with a global biotech with initial commercial collaboration potentially to be in the form of granting a partner an option to a future licence."
Before the Covidity announcement we had multiple shots on goal, now we have one more.
I am disappointed that so far the government have not given Scancell any funding but there may be reasons for this. It may be that a certain milestone in the research needs to be confirmed.
Sit tight, research the science, and await developments.
Ray,
Sorry, I have to agree with C7. Whether they are looking in out direction or looking at us, for certain we are less “under the radar”.
That has to be a good thing right? Maybe they are looking for a vaccine for Covid... oh, you do cancer vaccines as well?
Or maybe they are looking for cancer vaccines... oh, you do a Covid Vaccine as well?
Can’t wait for Wednesday.
Ray, I think that is a bit nit picky, If there was evidence I would have posted it, but you cannot say from findings from COVID19 that Pharma interest is less likely??
""Looking in our direction is not looking at us""
"now the Pharmas are looking in our direction via T-Cells"
We have no evidence that pharma have increased their interest in Scancell's Immunobody and Moditope platforms recently.
Any extra interest is behind closed doors.
Hi WTP, yeah just noticed the same thing.
As I mentioned yesterday, I wonder if it is by design or sheer coincidence that we are preparing to launch our platforms now the Pharmas are looking in our direction via T-Cells?? Interested in thoughts.
Interesting, although perhaps not unsurprisingly?(?) that are new posters here trying to gather info about the share, it sounds like all the talk of T-cells lately seems to have certainly piqued interest.
@symbo1 - I see you frequent the Omega Diagnostics board, a huge Covid riser, are people over there looking for their next Covid play?